Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients.

Nina DitschSabine HeubleinUdo JeschkeCornelia SattlerChristina KuhnAnna HesterBastian CzogallaFabian TrillschSven MahnerJutta EngelDoris MayrElisa Schmoeckel

Published in: Journal of cancer research and clinical oncology (2020)

Depending on nuclear or cytoplasmic expression, our study shows that THRα and its isoforms 1 and 2 provide different prognostic information for ovarian cancer patients. Further investigations should analyze if THRs may represent new endocrine targets for the treatment of ovarian cancer.

Keyphrases

poor prognosis
binding protein
long non coding rna
healthcare
health information
free survival